OMRIX Biopharmaceuticals Announces Positive Phase I Results With Fibrin Patch

(www.news.mayoclinic.com)OMRIX Biopharmaceuticals, Inc. ("OMRIX" or "the Company") (NASDAQ: OMRI), a biopharmaceutical Company that develops and markets biosurgical and passive immunotherapy products, announced the results of its prospective, open label, Phase I study of its novel Fibrin Patch. The results show that the Fibrin Patch appears to be safe as an adjunct to hemostasis. The fully absorbable Fibrin Patch, developed together with ETHICON, INC. [click link for full article]